Clinical trial NCT06383442: HIIT on Overweight Middle-aged Adults
Official title: Effects of Different Types of High Intensity Intermittent Training Combined With Resveratrol Supplementation on Oxidative Stress, Metabolic Adaption and Fat Loss in Aged and Overweight Groups
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight or Obesity
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants were evenly distributed according to a counterbalanced design and divided into three different groups by the body fat percentage of subjects: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest), 3. Control group. Target intensities of each interval bout, exercise and rest (Ex./R.), were 85-90% VO2peak/65-70% VO2peak zones, respectively.
Primary purpose: OTHER

Brief summary: 36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Detailed description: Aging, obesity, have been shown to lead to higher oxidative stress and chronic inflammation. However, high-intensity interval training (HIIT) has anti-inflammatory and anti-obesity benefits. Different training prescriptions may also affect improvements. Therefore, this study will explore the optimal HIIT prescription to improve fat, inflammation, metabolism, and exercise performance in overweight middle-aged and older adults. Thirty-six middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week), then the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Eligibility criteria: Inclusion Criteria:

* Recruit people who are overweight or obese (BMI between 24-35) who are 20-65 years old and have no exercise habits in a sitting lifestyle.

Exclusion Criteria:

* If there are any of the following circumstances, they are not allowed to participate in this research and are included in the listing conditions of this case:

  1. Have smoking and drinking habits.
  2. People who have stroke, type 1 and type 2 diabetes, neuromuscular disease, so that they cannot participate in physical activities.
  3. Chronic obstructive lung disease, asthma, interstitial lung disease or alveolar cyst fibrosis.
  4. Metabolic diseases include thyroid disease, kidney disease (kidney, bladder stones) or liver disease.
  5. Those with arrhythmia, a rhythm regulator, severe cardiovascular disease, peripheral vascular disease or cerebrovascular disease.
  6. People with epilepsy and rheumatoid arthritis.
  7. Those who have implanted artificial joints in the past six months and have had recent surgery.
  8. Migraine, acute thrombosis and hernia.
  9. Those who have engaged in strenuous exercise or have muscle aches within 24 hours before the experiment.
  10. People who feel unwell due to other reasons during the experiment.
  11. People with severe food allergies.
  12. Have hospitalization records within three months.
  13. People with cognitive impairment.
  14. Take any drugs that affect the function of the nervous system.

Primary outcomes:
measure: Aerobic Capacity Test
timeFrame: Primary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: Aerobic Capacity Test
timeFrame: Primary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: Anti-fatigue performance
timeFrame: Primary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: skinfold thickness
timeFrame: Primary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: Body composition_body fat
timeFrame: Primary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
Secondary outcomes:
measure: Glucose
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: Triglycerides
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: low-density lipoprotein (LDL)
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: high-density lipoprotein (HDL)
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: creatine kinase (CK) level
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: C-reactive protein (CRP)
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: tumor necrosis factor (TNF)-R1
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
measure: TNF-R2
timeFrame: were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University
Study officials:
References: